VerImmune
PrivateLast Round
Early Funding
Nov 24, 2025
Total Funding Raised
$7.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
VerImmune operates in Healthcare & Life Sciences and is based in Germantown, Maryland. Its latest recorded funding round was an Early Funding round in November 2025.
VerImmune is a biotechnology company developing a first-in-class cancer immunotherapy known as Anti-tumor Immune Redirection (AIR) that utilizes a proprietary virus-inspired particle technology to redirect pre-existing immune memory to fight cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VerImmune Comparables
Compare VerImmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trojan Bio | 84% | |
| KaliVir Immunotherapeutics | 81% | |
| Valo Therapeutics | 79% |
For institutional investors. Book with your work email.
VerImmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Nov 24, 2025 | ||||
| Grant | Apr 29, 2025 | ||||
| VC Round | Sep 23, 2024 | ||||
| Seed | Sep 20, 2023 | ||||
| Grant | Apr 29, 2023 | ||||
Seed | Jul 27, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
VerImmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Gaingels | Seed, VC Round |
| TEDCO | Early Funding |
| Ulu Ventures | Seed |
| SeedFolio | Seed |
| Proxima Ventures | VC Round |
| Beiley Biofund | VC Round |
| Proxima Ventures Ltd. | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 61% MoM, from 1.1K to 1.8K.
- Nov 24, 2025
Developing innovative Virus-inspired Particle (ViP) delivery technology.
For institutional investors. Book with your work email.
VerImmune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VerImmune's valuation, stock price, and market status.
Is VerImmune a public or private company?
VerImmune is a private company.
What is the current stock price of VerImmune?
VerImmune is a private company, so its shares have no public market price. Caplight tracks VerImmune's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VerImmune worth (valuation)?
Valuation information for VerImmune is not publicly available.
Can I buy VerImmune stock?
VerImmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VerImmune's last funding round?
VerImmune's most recent funding round was Early Funding on November 24, 2025.
Who are the main investors in VerImmune?
Key investors in VerImmune include TEDCO, SeedFolio, Beiley Biofund, Proxima Ventures Ltd..
Will VerImmune IPO soon?
No public IPO plans have been announced for VerImmune.
How can I track VerImmune secondary market activity?
Caplight tracks bids, offers, and trades in VerImmune's shares on secondary markets.